Rhapsido (Remibrutinib) Safety in Chronic Urticaria
How safe is remibrutinib (Rhapsido) for chronic spontaneous urticaria (CSU)? Dermatologists Dr. Ted Lain and Dr. Jason Hawkes break down bleeding risk, labs, drug interactions and patient counseling.
This sponsored episode of the Science of Skin Podcast, supported by Novartis, focuses on the safety of remibrutinib, an oral BTK inhibitor for chronic hives. Dr. Hawkes, Principal Investigator and Chief Scientific Officer at Oregon Medical Research Center, explains why the "bleeding events" in the phase 3 REMIX-1 and REMIX-2 trials were mostly mild bruising and petechiae, how fast onset and a…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.